Approves on use mough ut /31/2006 (1995).
U.S. Patient and Trandemark Chee, U.S. Delich (Sec.) U.S. Patient and Trandemark (Sec.) U.S. Delich (Sec

IATION DISCLOSURE	ı
MENT BY APPLICANT	
ibmission under 37 CFR 1.99)	(

Application Number		10749911
Filing Date		2003-12-30
First Named Inventor Avrito		ch et al.
Art Unit		2131
Examiner Name SHE		IKH, AYAZ R
Attorney Docket Number		FIS1P001

		· ·		U.S.	PATENTS		Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant Re			Lines where ges or Relevant
	1	6775382		2004-08-10	Al-Salqan			
	2	6192130		2001-02-20	Otway			
If you wis	h to a	dd additional U.S. Paten	t citatio	n information p	lease click the Add button.		Add	
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Releva		Lines where ges or Relevant
	1	20020144122		2002-03-10	Haughan et al.			
	2	20010037453		2001-11-01	Mitty et al.			
- 17	3	20020059144		2002-05-16	Meffert et al.			
	4	20050193075		2005-09-01	Haff et al.			
If you wisi	h to ac	dd additional U.S. Publis		•	n information please click the Ad	d button	Add	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Art Unit Examin

pplication Number		10749911
iling Date		2003-12-30
irst Named Inventor Avrito		th et al.
urt Unit		2131
xaminer Name	SHEI	KH, AYAZ R
Homou Docket Numb	or	FIS1P001

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	Ts
	1							_
If you wish	h to a	dd additional Foreign	Patent Docum	ent citation	information p	please click the Add butto	n Add	_
			NON-PA	TENT LITE	ERATURE DO	OCUMENTS	Remove	
Examiner Initials*	Examiner Cite include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the initials* No look, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.				Тŝ			
	1	International Search 2006.	Report and Writte	en Opinion I	n correspondin	g PCT Application No.: PCT	7/US04/43874, July 10,	
If you wis	h to a	dd additional non-pat	ent literature do	cument ci	tation informa	tion please click the Add	button Add	
				EXAMINE	R SIGNATU	RE		
Examiner	Signa	ature				Date Considered		
*EXAMIN	ER: Ir	itial if reference cons				formance with MPEP 60		_

See Kind Codes of UBPTO Patent Documents at swer_UBPTO_QDV or MPEP 601.04. * Enter office that issued the document, by the two-letter code (WIPO Standard ST3.) * For Lapraence patent documents, the archandard on the parent for the Emperor many precised the sensal number of the patent for sensal representations are considered to the document by the appropriate symbols as archandard on the document under WIPO Standard ST. 16 if possible. * Applicant is to place a check mark there if Engine Insurgues translations in attached.*

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10749911		
Filing Date First Named Inventor Avrito		2003-12-30		
		th et al.		
Art Unit		2131		
Examiner Name	SHEI	KH, AYAZ R		
Attorney Docket Number		FIS1P001		

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

	That each item of information contained in the information disclosure statement was first cited in any communication
7	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
_	information disclosure statement. See 37 CFR 1 97(eV1)

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 178(b) more than three months prior to the filing of the information disclosure statement. See 37 CFR 178(b) (2)

٦.	See attached certification statement	

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

□ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Torri or the signature.			
Signature	/ASH/	Date (YYYY-MM-DD)	2006-07-27
Name/Print	Alan S. Hodes	Registration Number	38185

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to life (and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12 Card 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. 0. Bot 1450, Alexandria, V.3.251.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. 0. Box 1450, Alexandria, V.3.231.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually the principal purpose and for examines your submission, which may visually intermediate or of extended now about the principal purpose.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuint to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.